Approach to latent tuberculosis infection screening before biologic therapy in ibd patients: Ppd or igra?

Simple item page
dc.contributor.authorHashash, Jana G.
dc.contributor.authorFadel, Carla Abou
dc.contributor.authorHosni, Mohammad N.
dc.contributor.authorHassoun, Lara
dc.contributor.authorKanafani, Zeina A.
dc.contributor.authorRegueiro, Miguel D.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Gastroenterology and Hepatology
dc.contributor.departmentDivision of Infectious Diseases
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:58:31Z
dc.date.available2025-01-24T11:58:31Z
dc.date.issued2020
dc.description.abstractThe use of biological agents for the treatment of chronic inflammatory conditions such as inflammatory bowel diseases (IBD) has been on the rise.1,2 Current biological therapies include antitumor necrosis factor-A (anti-TNF-A), anti-interleukin-12/23, and anti-integrin agents. Before initiation of biological drugs, screening for Mycobacterium tuberculosis infection is required to avoid reactivation or worsening of disease after immunosuppression. It has been shown that anti-TNF-A treated patients have a 14-fold increased risk of tuberculosis (TB) infection/reactivation compared with healthy controls.3 The methods for screening for TB have evolved over time and vary from region to region. © 2020 Oxford University Press. All rights reserved.
dc.identifier.doihttps://doi.org/10.1093/ibd/izaa139
dc.identifier.eid2-s2.0-85089620753
dc.identifier.pmid32483628
dc.identifier.urihttp://hdl.handle.net/10938/31338
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofInflammatory Bowel Diseases
dc.sourceScopus
dc.subjectBiologic therapy
dc.subjectIgra
dc.subjectPpd
dc.subjectQuantiferon-gold
dc.subjectAdult
dc.subjectBiological therapy
dc.subjectFemale
dc.subjectGastroenterology
dc.subjectHumans
dc.subjectInflammatory bowel diseases
dc.subjectInterferon-gamma release tests
dc.subjectLatent tuberculosis
dc.subjectMale
dc.subjectMass screening
dc.subjectMycobacterium tuberculosis
dc.subjectPractice guidelines as topic
dc.subjectTuberculin test
dc.subjectBcg vaccine
dc.subjectInfliximab
dc.subjectTuberculin
dc.subjectAccuracy
dc.subjectBcg vaccination
dc.subjectCd8+ t lymphocyte
dc.subjectCrohn disease
dc.subjectDisease severity
dc.subjectEnzyme linked immunosorbent assay
dc.subjectHuman
dc.subjectInfection prevention
dc.subjectInfection risk
dc.subjectInflammatory bowel disease
dc.subjectInterferon gamma release assay
dc.subjectMedication therapy management
dc.subjectPriority journal
dc.subjectReview
dc.subjectScreening test
dc.subjectTuberculosis
dc.subjectUlcerative colitis
dc.subjectAdverse event
dc.subjectMicrobiology
dc.subjectPractice guideline
dc.subjectProcedures
dc.titleApproach to latent tuberculosis infection screening before biologic therapy in ibd patients: Ppd or igra?
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2020-6566.pdf
Size:
121.95 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine